20/20 Biolabs, Inc. (AIDX) stock
AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/3062% below fair value
$0.20+0.00 (+0.25%)
Close on Nov 13, 2026Market cap $2.61MP/E –Yield –
20/20 Biolabs cash
Cash and short-term investments held at the end of each period.
20/20 Biolabs's cash was $4.55M at Jun 30, 2026. For fiscal 2025 it was $1.03M, down 42.5% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03M | -42.5% |
| FY2024 | Dec 31, 2024 | $1.78M | -56.4% |
| FY2023 | Dec 31, 2023 | $4.09M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.55M | +191.8% |
| Q1 FY2026 | Mar 31, 2026 | $4.22M | +136.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.03M | -74.9% |
| Q2 FY2025 | Jun 30, 2025 | $1.02M | – |
| Q1 FY2025 | Mar 31, 2025 | $1.56M | – |
| Q4 FY2024 | Dec 31, 2024 | $1.78M | – |
| Q4 FY2023 | Dec 31, 2023 | $4.09M | – |
See a number that looks wrong?